AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia

AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...
Medscape

New Class of Drug May Vanquish CLL

December 29, 2011 — Navitoclax, a novel BH3 mimetic that blocks the function of BCL-2, has shown significant antileukemic activity in patients with chronic lymphocytic leukemia (CLL) in a phase 1 ...
PharmiWeb

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...